ArticlePloS one2026
HDAC2 restrains IGF2BP1-associated m6A dysregulation in cervical cancer immunotherapy resistance.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer (CC) immunotherapy resistance remains a critical clinical challenge. Although immune checkpoint blockade shows efficacy in subsets of patients, the epigenetic and post-transcriptional mechanisms driving resistance are poorly understood. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), an m6A "reader," is implicated in tumor progression, but its role in CC immunotherapy resistance is undefined. The aim of this study was to elucidate the function of epigenetic regulator IGF2BP1 and HDAC2 in CC acquired immunotherapy resistance.
methodsMulti-omics analysis of GEO/TCGA datasets identified immunotherapy response related genes. Functional validation employed siRNA knockdown, overexpression, in vitro co-culture assay treated with anti-PD-1. Molecular mechanisms were assessed via RIP/MeRIP-qPCR, ChIP-qPCR, and luciferase reporter experiments.
resultsIGF2BP1 was significantly upregulated in CC tissues and cell lines (HeLa, SiHa, CaSki, C-33A), correlating with poor survival (P < 0.001). IGF2BP1 knockdown suppressed proliferation and sensitized tumors to anti-PD-1 via enhancing CD8 ⁺ T cell infiltration and IFNγ secretion. Mechanistically, IGF2BP1 stabilized immune-response genes and stemness program genes (PD-L1, WNT4, POU5F1, MYC) via m6A-dependent mRNA processing. HDAC2 was differentially associated with PD-1 treatment response, suggesting a context-dependent function and potential value as an exploratory biomarker of immunotherapy responsiveness. HDAC2 repressed IGF2BP1 transcription by erasing H3K27ac marks at its promoter. Targeting above axis synergistically enhanced T cells activation and toxic function.
conclusionsWe unveil an HDAC2/IGF2BP1/m6A axis is associated with cervical cancer immunotherapy resistance. HDAC2 loss derepresses IGF2BP1, stabilizing immunosuppressive and stemness-related transcripts via m6A modification. Targeting this axis partially restores PD-1 efficacy, providing a novel insight of cervical cancer immunotherapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.